Evolving paradigms in the treatment of opioid-induced bowel dysfunction

Epidemiology and Burden of Chronic Constipation

(2016) Maria Ines Pinto Sanchez et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

The ‘Mystery’ of Opioid-Induced Diarrhea

(2016) Silviu Bril et al.   Pain Research & Management

Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation

(2015) Jan Gaertner et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation

(2015) M. Camilleri et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation

(2014) L. Webster et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation

(2014) Celeste B. Burness et al.   DRUGS

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

(2014) Khanh Bui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol

(2014) Khanh Bui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain

(2014) William D. Chey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and Tolerability of Tapentadol Prolonged Release Compared With Prior Opioid Therapy for the Management of Severe, Chronic Osteoarthritis Pain

(2013) Ilona Steigerwald et al.   CLINICAL DRUG INVESTIGATION

New treatment possibilities for opioid-induced bowel dysfunction

(2013) Wojciech Leppert   PAIN

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation

(2013) Lynn Webster et al.   PAIN

Differences between opioids: pharmacological, experimental, clinical and economical perspectives

(2012) Asbjørn M. Drewes et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Methadone but not Morphine Inhibits Lubiprostone-Stimulated Cl− Currents in T84 Intestinal Cells and Recombinant Human ClC-2, but not CFTR Cl− Currents

(2012) John Cuppoletti et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Opioid-Induced Bowel Dysfunction

(2012) Christina Brock et al.   DRUGS

Low absolute bioavailability of oral naloxone in healthy subjects

(2012) Kevin Smith et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Constipation in Palliative Care: What Do We Use as Definitions and Outcome Measures?

(2012) Katherine Clark et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Misuse of Medicines in the European Union: A Systematic Review of the Literature

(2012) Alicia Casati et al.   EUROPEAN ADDICTION RESEARCH

Validated tools for evaluating opioid-induced bowel dysfunction

(2011) Anne Estrup Olesen et al.   ADVANCES IN THERAPY

Opioid-Induced Constipation: Challenges and Therapeutic Opportunities

(2011) Michael Camilleri   AMERICAN JOURNAL OF GASTROENTEROLOGY

Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose

(2011) S. WIRZ et al.   EUROPEAN JOURNAL OF CANCER CARE

Novel opioid antagonists for opioid-induced bowel dysfunction

(2011) Laura Diego et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lubiprostone for the treatment of opioid-induced bowel dysfunction

(2011) Banny S Wong et al.   EXPERT OPINION ON PHARMACOTHERAPY

Laxatives or methylnaltrexone for the management of constipation in palliative care patients

(2011) Bridget Candy et al.   Sao Paulo Medical Journal

Gastrointestinal side effects in chronic opioid users: results from a population-based survey

(2010) S. F. COOK et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Opiate-induced oesophageal dysmotility

(2010) R. E. KRAICHELY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tramadol-induced oral dryness and pilocarpine treatment: Effects on total protein and IgA

(2010) H. Looström et al.   ARCHIVES OF ORAL BIOLOGY

Tapentadol hydrochloride: A centrally acting oral analgesic

(2010) William E. Wade et al.   CLINICAL THERAPEUTICS

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation

(2010) Cornelius E. J. Sloots et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

(2010) Robert Buynak et al.   EXPERT OPINION ON PHARMACOTHERAPY

Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation

(2010) J. D. Belsey et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain

(2010) a. k. tuteja et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain

(2010) James E. Wild et al.   Pain Practice

Opioid Bowel Dysfunction and Narcotic Bowel Syndrome: A Population-Based Study

(2009) Rok Seon Choung et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial

(2009) O Löwenstein et al.   EXPERT OPINION ON PHARMACOTHERAPY

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

(2009) A. M. Rentz et al.   JOURNAL OF MEDICAL ECONOMICS

Gut peristalsis is governed by a multitude of cooperating mechanisms

(2008) Jan D. Huizinga et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

(2008) K. Simpson et al.   CURRENT MEDICAL RESEARCH AND OPINION

Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus

(2008) Michael D Kraft   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lubiprostone: chronic constipation and irritable bowel syndrome with constipation

(2008) Brian E Lacy et al.   EXPERT OPINION ON PHARMACOTHERAPY

Analgesic Efficacy and Safety of Oxycodone in Combination With Naloxone as Prolonged Release Tablets in Patients With Moderate to Severe Chronic Pain

(2008) Dana Vondrackova et al.   JOURNAL OF PAIN

Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study

(2008) Russell K. Portenoy et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness

(2008) Jay Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

(2008) Lynn Webster et al.   PAIN

The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)

(2008) Timothy J. Bell et al.   PAIN MEDICINE

Opioid-Induced Bowel Dysfunction

(2007) Jay Thomas   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT